Latest ArticlesThis study utilized the Delphi method to screen the core content and training formats of specialized training courses for clinical research, enhancing the specificity of clinical research training and ensuring the high-quality conduct of clinical studies.
Utilizing the Delphi method, 16 relevant domain experts were invited to conduct two rounds of scoring. Based on the weighted average score, total score, coefficient of variation and full score ratio, the framework of standardized clinical research course was comprehensively established, and the content of training, course duration, training formats and assessment methods were clearly defined.
The positive coefficients for both rounds of experts were 1.00. In the first round, the authoritative coefficients for course content, duration, training formats and assessment methods were 0.80, 0.89, 0.88, and 0.81, respectively. In the second round, these coefficients were 0.85, 0.90, 0.91 and 0.94, respectively. The coordination coefficients for the second round were 0.60, 0.87, 0.65 and 0.67, respectively, indicating a consistent trend of expert opinions. According to the expected value (EV) comprehensive assessment, the top ten training contents include: classification and basic statistical analysis of clinical research data (EV=1.00), key points and standards in clinical research design (EV=2.13), topic selection and research classification in clinical research (EV=3.13), data collection and process management in clinical research (EV=4.63), scientific initiation and ethical review in clinical research (EV=5.75), case report form design and preparation (EV=6.38), clinical research data quality check and control points (EV=6.50), clinical research relevant management requirements (EV=7.63), academic paper writing key points and standards (EV=8.63), clinical research data sets and statistical analysis (EV=9.50). The optimal training duration is 45 minutes, with on-site lectures as the preferred training format and assessment based on classroom participation and post-training written tests.
The ten most essential training contents were identified, the optimal training duration, format and assessment method were determined. It is recommended that in the future development of clinical research training courses, reference to and active adoption of the aforementioned training model could improve training effectiveness, enhance the clinical research capabilities of medical personnel, provide new ideas and directions for clinical medication.
Iron deficiency affects about a third of the global population and is particularly common in the elderly, women and those with certain chronic conditions. Iron deficiency has adverse effects on coronary artery disease, heart failure, pulmonary hypertension, and patients undergoing cardiac surgery, with approximately 50% of patients with heart failure and pulmonary hypertension having iron deficiency. The widespread use of antithrombotic drugs increases the risk of bleeding, which in turn increases the incidence of hemorrhage-related iron deficiency anemia. Recent studies have shown that iron supplementation can significantly improve quality of life and readmission rates in heart failure patients with reduced ejection fraction. However, the mechanism of its action in various cardiovascular diseases is still unclear. Based on the evidence of the benefits of iron supplementation in various cardiovascular diseases, this article reviewed the mechanism and potential benefits of iron supplementation in various cardiovascular diseases.
Primary immune thrombocytopenia (ITP) is an autoimmune disease characterized by increased platelet destruction and inadequate megakaryocyte maturation. In recent years, with the in-depth study of the pathogenesis of ITP, new drugs related to spleen tyrosine kinase, Bruton's tyrosine kinase, neonatal Fc receptor inhibitors, platelet desialylation, B-cell activating factor and classical complement pathway have gradually become the focus of ITP treatment. This article reviewed the research progress on new ITP drugs in recent years, aiming to provide reference for selecting appropriate individualized treatment according to the pathogenesis and economic situation in the future.
All-trans-retinoic acid (ATRA) is the clinical choice for the treatment of acute promyelocytic leukemia. However, in recent years, a large number of studies have shown that ATRA maintains the human normal immune microenvironment by inhibiting the immune escape effect of tumor stem cells and promoting the differentiation of myeloid-derived suppressor cells, and enhances the efficacy of chemotherapeutic drugs, targeted drugs and immunotherapy drugs in solid tumors. This paper reviewed the clinical trial progress of ATRA in solid tumors to provide a reference for its further clinical application.
Triple-negative breast cancer (TNBC) is aggressive, prone to recurrence and metastasis. There is a higher risk of early recurrence and a worse prognosis compared to other types of breast cancer. Due to the lack of specific therapeutic targets, the first-line treatment recommendations for metastatic TNBC (mTNBC) in China are still mainly based on anthracycline or paclitaxel as monotherapy or combination chemotherapy. In recent years, with the successful application of new therapeutic drugs in mTNBC, some new drugs have been approved for the treatment of mTNBC abroad. This article reviewed the recent advances in mTNBC molecular typing, immunity and antibody drug conjugations.
Angiogenesis plays a key role in the growth, local invasion and distant metastasis of a variety of solid tumors. At present, anti-angiogenesis drugs can be divided into three types: small-molecule multi-target, macromolecule single-target and endogenous pan-target angiogenesis inhibitors. Among them, small molecule anti-angiogenesis inhibitors mainly inhibit tumor angiogenesis by simultaneously or sequentially targeting multiple growth factors/pathways, and can effectively inhibit drug resistance generated by tumor cells. At the same time, small molecule anti-angiogenesis inhibitors have the advantages of good tissue permeability and convenient administration. At present, it has been widely used in the combination therapy of various solid tumors. This paper reviewed the targeted therapy of small molecule anti-angiogenic tyrosine kinase inhibitors and their clinical progress and safety in multiple solid tumors.
To explore the effects of Banzhilian formula on the expression levels of tumor necrosis factor-like weak inducer of apoptosis (TWEAK), fibroblast growth factor-inducible (Fn)-14, and lipocalin (Lcn)-2 in the psoriatic mouse skin tissue induced by imiquimod, and to investigate the mechanism of action.
A total of 21 BALB/c male mice were randomly divided into control group, model group and intervention group, with 7 mice in each group. The control group was given Vaseline and 0.9% sodium chloride injection intragastric administration, the model group was given imiquimod and 0.9% sodium chloride injection intragastric administration, and the intervention group was given imiquimod and Banzhilian formula intragastric administration for 7 consecutive days. The psoriasis area and severity index (PASI) scores in each group were compared. Hematoxylin eosin staining was used to observe the pathological changes of skin tissue. The expressions of Ki-67, Fn-14 and Lcn-2 in skin lesions were detected by immunohistochemistry. The levels of Fn-14 and Lcn-2 in skin lesions were detected by western blot. TWEAK content in skin lesions was determined by enzyme linked immunosorbent assay. The mRNA expression of TWEAK, Fn-14 and Lcn-2 were detected by quantitative polymerase chain reaction.
Compared with the model group, the severity of skin erythema and scales in the intervention group were reduced, PASI score and the number of Ki-67 positive cells were decreased, the mRNA and protein expression of TWEAK, Fn-14, and Lcn-2 in the lesion tissues were significant decreased (P<0.05).
Banzhilian formula can improve imiquimod-induced skin inflammatory response in mouse psoriasis model, possibly by inhibiting TWEAK/Fn-14 signaling pathway.
To explore the clinical efficacy of candesartan combined with amlodipine on essential hypertension (EH).
A total of 120 EH patients admitted to our hospital from February 2022 to January 2023 were selected and divided into observation group (amlodipine+candesartan) and control group (amlodipine) according to random number table method, with 60 cases in each group. The course of treatment for all patients was 8 weeks. The efficacy, ambulatory blood pressure [coefficient of variation in daytime systolic blood pressure (SCV), coefficient of variation in nocturnal systolic blood pressure (nSCV), coefficient of variation of 24-hour systolic blood pressure (24hSCV), coefficient of variation in daytime diastolic blood pressure (DCV), coefficient of variation in nocturnal diastolic blood pressure (nDCV), coefficient of variation of 24-hour diastolic blood pressure (24hDCV)], carotid intimal medial thickness (IMT), stromal interaction molecule (STIM)1 and occurrence of adverse reactions of the two groups were compared between the two groups.
After treatment, the total clinical effective rate of the observation group was higher than that of the control group (98.33% vs 80.00%), the difference was statistically significant (P<0.05). SCV, nSCV, 24hSCV, DCV, nDCV, 24hDCV, IMT and STIM1 were all decreased in both groups, and the observation group was lower than the control group (P<0.05). The incidence of adverse reactions was 3.34% in both groups, with no statistical significance (P>0.05).
Candesartan combined with amlodipine can effectively reduce blood pressure variability, IMT and STIM1 levels in EH patients, improve prognosis and clinical efficacy.
To observe the clinical efficacy of Molian Qubai decoction combined with 308 nm excimer laser in treating vitiligo of kidney deficiency and blood stasis type.
A total of 86 patients with vitiligo of kidney deficiency and blood stasis type were divided into control group and study group by simple ranking random scheme and the random number table method, with 43 cases in each group. The control group received 308 nm excimer laser, and the study group received Molian Qubai decoction combined with 308 nm excimer laser. The efficacy, white spot area, white spot resolution time, immunoglobulin (Ig) G, IgM, IgA, serum complement hemolytic activity (CH50), T lymphocyte subpopulations, and adverse reactions in the two groups were compared.
The total effective rate of the study group was higher than that of the control group (90.70% vs 72.09%, P<0.05). After treatment, the vitiligo area score index, and the levels of IgG, IgM, and IgA in both groups were lower than before treatment (P<0.05), and the study group were lower than the control group (P<0.05). The time for white spot regression in the study group was earlier than that in the control group (P<0.05). After treatment, the levels of CH50, CD3+, CD4+, CD4+/CD8+ in both groups were higher than before treatment (P<0.05), and the study group was higher than the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).
The combination of Molian Qubai decoction and 308 nm excimer laser can enhance the immune function of patients with vitiligo of kidney deficiency and blood stasis type, reduce the area of white spots, accelerate the resolution of white spots, improve the therapeutic effect, and do not increase adverse reactions.